Literature DB >> 10942116

Application and evaluation of denaturing HPLC for molecular genetic analysis in tuberous sclerosis.

A C Jones1, J R Sampson, B Hoogendoorn, D Cohen, J P Cheadle.   

Abstract

Tuberous sclerosis (TSC) is an autosomal dominant disorder characterised by the development of hamartomas in multiple tissues and organs. TSC exhibits locus heterogeneity with genes at 9q34 (TSC1) and 16p13.3 (TSC2) that have 21 and 41 coding exons, respectively. The mutational spectrum at both loci is wide and previous studies have shown that 60%-70% of cases are sporadic and represent new mutations. We have formatted denaturing high performance liquid chromatography (DHPLC) for rapid screening of all coding exons of TSC1 and TSC2. DHPLC analysis detected likely disease-causing mutations in 103 of 150 unrelated cases (68%), compared with 92/150 (61%) and 87/150 (58%) for single-strand conformation polymorphism analysis (SSCP) and conventional heteroduplex analysis (HA), respectively. Capital, consumable and labour costs were determined for each exon screening procedure. Estimated costs per patient sample depended on throughput, particularly for DHPLC, where a high proportion of costs are fixed, and were pounds sterling 257, pound sterling 216 and pound sterling 242 for DHPLC, SSCP and HA, respectively, assuming a throughput of 252 samples per year, or pound sterling 354, pound sterling 233 and pound sterling 259, assuming a throughput of 126 samples per year. DHPLC had the advantages of increased sensitivity and reduced labour costs when compared with more traditional approaches to exon screening but, unless expensive DHPLC equipment is being efficiently utilised for a very high proportion of the time available, overall costs are slightly higher.

Entities:  

Mesh:

Year:  2000        PMID: 10942116     DOI: 10.1007/s004390000316

Source DB:  PubMed          Journal:  Hum Genet        ISSN: 0340-6717            Impact factor:   4.132


  12 in total

1.  Characterisation of TSC1 promoter deletions in tuberous sclerosis complex patients.

Authors:  Ans M W van den Ouweland; Peter Elfferich; Bernard A Zonnenberg; Willem F Arts; Tjitske Kleefstra; Mark D Nellist; Jose M Millan; Caroline Withagen-Hermans; Anneke J A Maat-Kievit; Dicky J J Halley
Journal:  Eur J Hum Genet       Date:  2010-09-29       Impact factor: 4.246

2.  Rapid mutation scanning of genes associated with familial cancer syndromes using denaturing high-performance liquid chromatography.

Authors:  D J Marsh; G Theodosopoulos; V Howell; A L Richardson; D E Benn; A L Proos; C Eng; B G Robinson
Journal:  Neoplasia       Date:  2001 May-Jun       Impact factor: 5.715

3.  Isolation and growth of smooth muscle-like cells derived from tuberous sclerosis complex-2 human renal angiomyolipoma: epidermal growth factor is the required growth factor.

Authors:  Elena Lesma; Vera Grande; Stephana Carelli; Diego Brancaccio; Maria Paola Canevini; Rosa Maria Alfano; Guido Coggi; Anna Maria Di Giulio; Alfredo Gorio
Journal:  Am J Pathol       Date:  2005-10       Impact factor: 4.307

4.  Mutational analysis in a cohort of 224 tuberous sclerosis patients indicates increased severity of TSC2, compared with TSC1, disease in multiple organs.

Authors:  S L Dabora; S Jozwiak; D N Franz; P S Roberts; A Nieto; J Chung; Y S Choy; M P Reeve; E Thiele; J C Egelhoff; J Kasprzyk-Obara; D Domanska-Pakiela; D J Kwiatkowski
Journal:  Am J Hum Genet       Date:  2000-12-08       Impact factor: 11.025

5.  Assay validation for identification of hereditary nonpolyposis colon cancer-causing mutations in mismatch repair genes MLH1, MSH2, and MSH6.

Authors:  Madhuri Hegde; Maria Blazo; Belinda Chong; Tom Prior; Carolyn Richards
Journal:  J Mol Diagn       Date:  2005-10       Impact factor: 5.568

6.  Determining the pathogenicity of patient-derived TSC2 mutations by functional characterization and clinical evidence.

Authors:  Elaine A Dunlop; Kayleigh M Dodd; Stephen C Land; Peter A Davies; Nicole Martins; Helen Stuart; Shane McKee; Chris Kingswood; Anand Saggar; Isabel Corderio; Ana Maria Duarte Medeira; Helen Kingston; Julian R Sampson; David Mark Davies; Andrew R Tee
Journal:  Eur J Hum Genet       Date:  2011-03-16       Impact factor: 4.246

7.  The methylation of the TSC2 promoter underlies the abnormal growth of TSC2 angiomyolipoma-derived smooth muscle cells.

Authors:  Elena Lesma; Silvia Maria Sirchia; Silvia Ancona; Stephana Carelli; Silvano Bosari; Filippo Ghelma; Emanuele Montanari; Anna Maria Di Giulio; Alfredo Gorio
Journal:  Am J Pathol       Date:  2009-05-14       Impact factor: 4.307

8.  Hypoxia-inducible factor-1alpha polymorphisms and TSC1/2 mutations are complementary in head and neck cancers.

Authors:  Carla Hebert; Kathleen Norris; Pallavi Parashar; Robert A Ord; Nikolaos G Nikitakis; John J Sauk
Journal:  Mol Cancer       Date:  2006-01-16       Impact factor: 27.401

9.  Molecular and clinical analyses of 84 patients with tuberous sclerosis complex.

Authors:  Chia-Cheng Hung; Yi-Ning Su; Shu-Chin Chien; Horng-Huei Liou; Chih-Chuan Chen; Pau-Chung Chen; Chia-Jung Hsieh; Chih-Ping Chen; Wang-Tso Lee; Win-Li Lin; Chien-Nan Lee
Journal:  BMC Med Genet       Date:  2006-09-18       Impact factor: 2.103

10.  TSC2 epigenetic defect in primary LAM cells. Evidence of an anchorage-independent survival.

Authors:  Elena Lesma; Silvia Ancona; Silvia M Sirchia; Emanuela Orpianesi; Vera Grande; Patrizia Colapietro; Eloisa Chiaramonte; Anna Maria Di Giulio; Alfredo Gorio
Journal:  J Cell Mol Med       Date:  2014-03-07       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.